MCET (MultiCell Technologies) Market Cap: $0.00 Mil (As of Jul. 08, 2026)


What is MultiCell Technologies Market Cap?

MultiCell Technologies MCET -90.00% Market Cap is $0.00 Mil as of Jul. 08, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MultiCell Technologies's share price for the quarter that ended in Aug. 2015 was $0.0003. MultiCell Technologies's Shares Outstanding (EOP) for the quarter that ended in Aug. 2015 was 5,000.95 Mil. Therefore, MultiCell Technologies's market cap for the quarter that ended in Aug. 2015 was $1.50 Mil.

MultiCell Technologies's quarterly market cap increased from Feb. 2015 ($1.46 Mil) to May. 2015 ($2.00 Mil) but then declined from May. 2015 ($2.00 Mil) to Aug. 2015 ($1.50 Mil).

MultiCell Technologies's annual market cap increased from Nov. 2012 ($1.75 Mil) to Nov. 2013 ($1.83 Mil) and increased from Nov. 2013 ($1.83 Mil) to Nov. 2014 ($2.28 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MultiCell Technologies's Enterprise Value for Today is $0.00 Mil.

MultiCell Technologies  (OTCPK:MCET) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

MultiCell Technologies Market Cap Related Terms

MultiCell Technologies Market Cap Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Market Cap Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.91 4.03 1.75 1.83 2.28

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 2.28 1.46 2.00 1.50

MCET vs ERGO, OPLI, GLAG: Market Cap Comparison

For the Biotechnology subindustry, MultiCell Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Market Cap distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Market Cap falls into.


MultiCell Technologies Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

MultiCell Technologies's Market Cap for the fiscal year that ended in Nov. 2014 is calculated as

Market Cap (A: Nov. 2014 )=Share Price (A: Nov. 2014 )*Shares Outstanding (EOP) (A: Nov. 2014 )
=$0.0005*4552.801
=$2.28

MultiCell Technologies's Market Cap for the quarter that ended in Aug. 2015 is calculated as

Market Cap (Q: Aug. 2015 )=Share Price (Q: Aug. 2015 )*Shares Outstanding (EOP) (Q: Aug. 2015 )
=$0.0003*5000.949
=$1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.00 Mil mean?
MultiCell Technologies (MCET) has a Market Cap of $0.00 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Market Cap too high?
MultiCell Technologies' current Market Cap is $0.00 Mil.
How does MultiCell Technologies' Market Cap compare to ERGO and OPLI?
MultiCell Technologies' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 121.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MultiCell Technologies and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MultiCell Technologies's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Market Cap is $0.00 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.